NO platform allows you to synthesize original hybrid molecules consisting of pharmaceutically active compounds (API), prostaglandins (PG) and nitric oxide donors (NO-donors)
Main News
* Gurus successfully completed preclinical trials of asthma treatment drug * Magazine Kommersant published an article about promising multifunctional drug candidates of Gurus BioPharm * Gurus raises $0.7M for preclinical trials of a drug for asthma

Why to invest in biomedical innovations

Yield of investments in innovative drug development is 540% for 5 years 

Poliwogg Medical Breakthroughs Index


Investments in innovations from several sectors (Software, Tech Services, Healthcare, Telecom, Consumer Services) showed a yield of 400% for 7 years. It is lower than yield of biomedical innovation, but far ahead of all other indices

Thomson Reuters Venture Capital Indices